In this week’s edition of InnovationRx, we look at the impact of Trump’s proposed budget cuts on biomedical research and ...

Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal ...

The Cambridge Independent Business Awards 2025 are now open for entry. Following the success of our inaugural awards last year, we are delighted to announce that the search is now on for the best in ...

AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus pertuzumab reduced the ...

After rapid expansion, signs of a slowdown raise questions about future opportunities in the sector When it emerged that ...

AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free survival in early stage ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a ...

AstraZeneca PLC has agreed to pay $51 million to settle claims it entered into an unlawful deal to limit competition for ...

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...

Survival rates among breast cancer patients whose cancer is detected before it spreads are high, between 86% and 89%. Yet if ...

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) ...